Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

NMP to Evaluate Technology to Create New Class of PET Radiopharmaceuticals

TOKYO–(BUSINESS WIRE)–Fuzionaire Radioisotope Technologies K.K. (�FRIT”) today announced that it has entered into a feasibility study agreement with Nihon Medi-Physics Co., Ltd. (“NMP”), a leading radiopharmaceutical company in Japan, engaged in R&D, manufacturing, and distribution.

Founded in 2019, FRIT is a joint venture between radiopharmaceutical companies Fuzionaire Diagnostics, Inc. (“Fuzionaire Dx”) and Japan Medical Isotope Technology Development K.K. to develop and commercialize Fuzionaire Dx’s radiopharmaceutical technologies in Japan. Founded in 1973, NMP is a joint venture between Sumitomo Chemical Company, Limited and GE Healthcare.

Under the agreement, NMP will evaluate the ability of Fuzionaire Dx’s technology to create a new class of positron emission tomography (PET) radiopharmaceuticals. Fuzionaire Dx’s fluorine-18 radiolabeling platform, powered by a breakthrough in fundamental chemistry out of Nobel Prize winner Robert H. Grubbs’ laboratory at Caltech, allows the incorporation of fluorine-18 into a broad range of ligands at record-breaking speed.

One of FRIT’s priorities is to apply this fluorine-18 platform to create new radiopharmaceuticals that enable the prediction and measurement of patient responses to cancer immunotherapy treatments. In recent years, there have been extraordinary advances in treatments that help patients’ immune systems fight cancer. However, accurate, optimized patient stratification and selection remains a critical barrier to effective application and development of immunotherapies. Due to the unique capabilities of positron emission tomography – specific, quantitative, real-time, and high-resolution imaging of markers of immunological response – new PET radiopharmaceuticals have the potential to remove that barrier.

About Nihon Medi-Physics Co., Ltd.

Nihon Medi-Physics Co., Ltd. (NMP) is a leading company for radiopharmaceuticals in Japan, engaged in R&D, manufacturing, and distribution. NMP’s stable and reliable supply of quality products has contributed to society over the years. With continuous challenges to new business opportunities in the “Development of Theranostics,” “Application of digital technology in healthcare” and “Expansion of radiopharmaceutical business in Asia,” NMP anticipates to further contribute to the health and well-being of societies into the future.

Please visit our website for more information. https://www.nmp.co.jp/eng/

About Fuzionaire Radioisotope Technologies K.K.

Fuzionaire Radioisotope Technologies K.K. (“FRIT”) is a Tokyo-based radiopharmaceutical company commercializing Fuzionaire Diagnostics’ technology in Japan, expanding Fuzionaire Dx’s fluorine-18 radiolabeling platform through partnerships with Japanese pharmaceutical companies and research institutions. The company is also developing new alpha-emitting radiotherapeutics using Fuzionaire Dx’s chemistry.

About Japan Medical Isotope Technology Development K.K.

Japan Medical Isotope Technology Development K.K. (“JAMIT”) is a Tokyo-based company. JAMIT is in the business of developing new technologies for creating medical isotopes and radiopharmaceuticals. It was co-founded in 2019 by pharmaceutical executives Takeo Morooka, MD, MPH, and Masanori Shibuya.

About Fuzionaire Diagnostics, Inc.

Fuzionaire Diagnostics (“Fuzionaire Dx”) is a nuclear medicine company on a mission to improve disease, diagnosis, and treatment.

Our patented molecular scaffolds enable efficient, late-stage incorporation of radioisotopes into diagnostic pharmaceuticals. This offers researchers and clinicians a new strategy for improved diagnosis, monitoring, and treatment of numerous diseases, and the acceleration of drug development.

Our new chemistry makes possible the production of a broad range of fluorine-18 radiopharmaceuticals on-demand. This approach can decentralize the process of radiopharmaceutical manufacture and PET scan administration, addressing a limiting factor in precision medicine today.

For more, visit us at: www.fuzionairedx.com.

Contacts

Shannia Coley

443 471 6830

Jones-Dilworth, Inc.